MXP (Methoxphenidine) Crystal research chemical in crystalline form
MXP (Methoxphenidine) Crystal Price range: € 22,00 through € 80,00
Back to products
Bromazolam Blister 10x 2.5mg ten-tablet research material packaging
Bromazolam Blister - 10x 2.5mg Price range: € 25,90 through € 198,75

Bromazolam Pellets – 3mg

Price range: € 17,25 through € 725,00

Bromazolam Pellets 3mg are described as compressed laboratory research pellets with a nominal bromazolam content of 3 mg per unit.

Bromazolam is a brominated triazolobenzodiazepine structurally related to alprazolam. The source identifies the compound by CAS number 71368-80-4, molecular formula C17H13BrN4, and molecular weight 353.22 g/mol.

The supplied specifications describe resealable packaging, a typical ingredient-purity claim of at least 98% by HPLC, and a recommended storage range of 2–8°C.

The product brief also reports batch traceability, third-party laboratory testing, and pellet-weight consistency within ±2%. These claims have not been independently verified.

No batch-specific Certificate of Analysis, finished-pellet assay, or content-uniformity dataset was provided. The nominal 3 mg label claim therefore should not be interpreted as a verified measurement for every pellet.

Bromazolam is associated with serious benzodiazepine-related hazards, including sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12442 Category:
Description

Bromazolam Pellets 3mg – Research Material Information

Bromazolam Pellets 3mg – Product Overview

The source describes compressed research pellets containing bromazolam, a brominated triazolobenzodiazepine compound.

Each pellet carries a nominal label claim of 3 mg.

The product is presented for laboratory contexts involving chemical identification, structural characterization, chromatographic analysis, and analytical documentation.

The source describes the pellet format as providing consistent analytical portions. However, no finished-pellet assay or content-uniformity report was supplied to demonstrate that claim.

A stated nominal content is not equivalent to an independently verified finished-unit measurement.

Chemical Identity & Classification

Bromazolam belongs to the triazolobenzodiazepine class and is structurally related to alprazolam.

The supplied chemical specifications are:

  • Compound: Bromazolam
  • Reported systematic name: 8-Bromo-1-methyl-6-phenyl-4H-s-triazolo[4,3-a]benzodiazepine
  • CAS number: 71368-80-4, as supplied
  • Molecular formula: C17H13BrN4
  • Molecular weight: Approximately 353.22 g/mol
  • Product form: Compressed pellets
  • Nominal content: 3 mg per pellet

The molecular formula and reported molecular weight are internally consistent within rounding.

The supplied chemical identity and CAS assignment should nevertheless be confirmed against authoritative records and analytical evidence for the actual batch.

Public chemical-reference information can be reviewed through PubChem.

Chemical & Physical Characteristics

The product is described as a compressed pellet presentation.

No independently verified pellet dimensions, color specifications, excipient composition, hardness data, or disintegration measurements were supplied.

The source refers to dissolution behavior, solubility profiles, and stability under analytical conditions.

These properties can depend on the chemical form, formulation ingredients, and physical characteristics of the finished pellet.

No validated dissolution or quantitative-recovery dataset was provided.

The consistency of pellet appearance or total weight does not establish uniform bromazolam content.

Purity & Analytical Verification

The source reports a typical ingredient purity of at least 98% by HPLC.

It also claims analytical identity confirmation using HPLC, mass spectrometry, and NMR spectroscopy.

No chromatograms, spectra, impurity profiles, or batch-specific Certificate of Analysis were supplied.

The reported purity therefore remains unverified.

Ingredient purity and finished-pellet content are separate analytical characteristics.

A high-purity starting material does not establish that every compressed pellet contains exactly the nominal 3 mg quantity.

The source also describes LC-MS/MS and HPLC/UV analytical contexts. No validated method-performance results or certified reference values were provided.

Quality Control & Batch Integrity

The product brief claims batch traceability, third-party testing, residual-solvent analysis, homogeneity assessment, and content-uniformity testing.

It also reports pellet-weight consistency within ±2%.

These claims require supporting batch records and independent analytical documentation.

No such records were supplied.

Pellet-weight variation describes differences in total pellet mass.

It does not independently establish the distribution or quantity of bromazolam within individual units.

The source’s quality-control statements should therefore be treated as unverified supplier claims.

Safety, Handling & Laboratory Precautions

Bromazolam is a potent benzodiazepine-related central nervous system depressant.

Potential hazards include sedation, confusion, impaired coordination, memory impairment, dependence, and withdrawal complications.

Concurrent exposure to opioids, alcohol, or other central nervous system depressants can increase the risk of respiratory depression and other severe outcomes.

Institutional chemical-safety procedures should address restricted access, protective equipment, accidental-exposure response, contamination prevention, secure storage, and appropriate waste management.

No verified product-specific Safety Data Sheet was supplied.

The pellet format does not establish suitability for human or veterinary administration.

Packaging, Labeling & Storage

The source describes compressed pellets in resealable packaging.

It recommends storage in a cool, dry environment at approximately 2–8°C, protected from light and moisture.

No validated stability study was provided to establish this temperature range as a product-specific requirement.

No verified shelf life, packaging-barrier performance, or finished-product stability dataset was supplied.

Product labels should distinguish nominal content and supplier specifications from batch-verified analytical results.

Intended Research Use & Market Positioning

The source identifies analytical laboratory contexts involving triazolobenzodiazepine characterization, chromatographic profiling, and forensic chemical identification.

The material has not been established as a certified reference material or validated quantitative calibrator.

The supplied Raw Lab Chems catalog references are:

These products involve distinct benzodiazepine-related compounds and should not be represented as chemically equivalent or interchangeable.

Their inclusion is for catalog reference only.

Ordering, Availability & Fulfillment

The source claims international shipping, tracking, customs documentation, protective packaging, and compliance with IATA and DOT requirements.

No current inventory record, transport classification, carrier authorization, or supporting shipping documentation was supplied.

These claims cannot be independently confirmed.

Research-only labeling does not automatically exempt a substance from controlled-substance laws, analogue legislation, or import restrictions.

Legal authorization and transport eligibility depend on the applicable jurisdiction and transaction.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Bromazolam is a psychoactive benzodiazepine-related compound that may be subject to controlled-substance, analogue, chemical-safety, import, and export restrictions.

Institutions are responsible for verifying applicable legal requirements and maintaining appropriate authorization, laboratory controls, and secure custody.

No therapeutic approval, consumer-use authorization, or certified reference-material status is implied.

Additional information
Quantity (pellets)

25

,

50

,

100

,

250

,

500

,

1000

,

2500

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Bromazolam Pellets – 3mg”
Shipping & Delivery